Two interwoven processes, human genome sequencing and the development of new technologies using DNA as an analytical sample and as a reagent have resulted in the genetic revolution in different fields of medicine, such as the field of medical therapy leading to personalized medicine through pharmacogenetics approach.
heterozygotes for mutant alleles. The ultrarapid metabolizer (UM) phenotype is characterized by enhanced drug metabolism due to gene amplification. Individuals having this phenotype are prone to therapeutic failure because drug concentrations at normal doses are by far too low. Five to 20% of patients can belong to one of these risk groups, depending on the population studied. It is important to mention that there are significant ethnic and racial differences in the frequency of variant alleles.
Mechanisms of genetic variations
Genetic variations are the result of multiple mechanisms such as insertion, deletion, variable tandem repeats and microsatellites but the most frequent polymorphisms are point mutations or single nucleotide polymorphisms (SNPs), accounting for over 90%. Some of the polymorphisms are without consequences, but others cause altered protein, truncated protein, unstable protein or protein due to expression level. When we talk about a polymorphism, we mean a mutation in the genetic code that occurs in more than 1% of a population.
The potential of pharmacogenetics as a discipline in laboratory medicine
Pharmacogenomics and pharmacogenetics deal with the use of information derived from analysis of gene variations with objective to guide the drugs use. The pharmacogenomics studies are focused on the contribution of multiple genes (or entire genome) to drug response variability, whereas pharmacogenetics is focused on the association between single gene and drug response variability. Single gene testing can include pharmacodynamic genes, such as serotonin transporter or dopamine receptors, but these gene tests are not ready for clinical use yet, however, pharmacokinetic genes such as CYP2D6 and CYP 2C9 have reached clinical practice. Also, testing a limited number of multiple genes is possible by several commercial laboratories, providing batteries of genotype testing such as pharmacokinetic genes CYP2D6 and CYP2C19.
Pharmacogenetics has two functional components that link pharmacology to genetics. One may predict how drugs are processed by the body (pharmacokinetics) and the other how drugs interact with receptors to cause drug response (pharmacodynamics). Pharmacokinetics is strongly linked to biotransformation of drugs by metabolic processes mostly by the liver and their subsequent elimination by kidney function. The pharmacokinetic level uncludes gene polymorphisms that modify the concentration of a drug and its metabolites at the sites of their molecular action (such as polymorphisms of drug metabolizing enzymes, drug transporters, etc.). However, pharmacodynamics deals with understanding the drug interaction with receptors and the subsequent response. In this process some biotransformation may be involved. The pharmacodynamic level includes gene polymorphisms associated with the drug effect and mechanism of action, being unrelated to the drug concentration (receptors, ion channels, etc.).
Most of the studies were done on genes encoding for CYP450 enzyme family, the most important drug metabolizing enzyme. Most drug metabolizing enzymes exhibit clinically relevant genetic polymorphisms. The potential of pharmacogenetics in differentiating responders from nonresponders in a patient population with the same diagnosis is promising for its high practical implications, especially for drugs that are substrates of highly polymorphic enzymes. However, genetic variants linked to receptors have been studied too and represent a powerful direction in predicting drugs response.
Pharmacogenetic profiles
There are two approaches to creating genetic profiles enabling optimal treatment. The first approach implies making a specific hypothesis on the genes that cause therapeutic response modification and their testing in all individuals irrespective of their therapeutic response (gene candidates).
The second approach implies the search for so-called SNP profile (SNP prints) associated with efficient or adverse events in a respective population (forensic precision). This is known as the pharmacogenetic approach, i.e. search for SNP profile. According to literature data reported by experts in the field of pharmacogenetics, for clinical use preference is given to the search for SNP profile in individuals by whole genome scanning. Examples of specific genes modifying drug response, and which could be currently used in clinical practice are the genes encoding for drug metabolizing enzymes from the families CYP450, CYP2D6, 2C19 and 2C9, then phase II enzymes NAT2 and TPMT, B2-AR receptors, and some enzymes involved in the metabolism of antitumor drugs. The whole project has been divided into nine different sections, each of them chaired by an expert in the field, member of the Committee. The approach of the Committee was to establish a series of questions in each of the sections (outlined below), listed at the beginning of each section followed by a series of respective recommendations and accompanied by a list of most relevant references. The 10th section contains the glossary devoted to pharmacogenetics.
Guidelines and Recommendations in Pharmacogenetics
In this paper, the material issued by the New York National Academy In General introduction and scope the author describes the steps in this enormous work on the project as follow:
• The objective of this section is to give the reader a primer in the principals of drug metabolism and population genetics with sufficient basis for understanding how the concepts of genetics are applied in the development and application of pharmacogenetics testing as a discipline. Questions for consideration in this chapter were:
• What are the essential elements of drug pharmacokinetics and pharmacodynamics necessary to understand the application of pharmacogenetics in laboratory medicine? • What is the cytochrome P450 system and what are the relevant allele frequencies of these components (CYP2D6, CYP2C19, and CYP2C9)? • What are key considerations and recommendations for statistical sampling of the indicated alleles in populations?
The reader can find sufficient data for understanding drug metabolism, pharmacokinetics and pharmacodynamics as well as the connection between genotyping and drug dosing requirements and adverse drug reaction. The CYP P450 system and special CYP enzymes and recommendations for their use in pharmacogenetic testing, and how the allele distribution should be evaluated in a service to a reference population are described. 3. Payne D. Methodology and quality assurance considerations in pharmacogenetics testing (Reviewer: Carr J) (http://www.aacc.org/...)
The objective of the section is quality assurance and quality control issues. Questions for consideration were:
• What is the error rate for each test and each platform?
• This section is focused on the importance of how clinical laboratory is expected to provide services of pharmacogenetic testing consistent with the needs of healthcare providers. Questions for consideration were:
• What level of certification should be required for clinical laboratories and personnel performing pharmacogenetics testing? • What are the recommended specimens for testing?
• What should be the primary test-result output?
• What test result turn-around times are optimal for pharmacogenetics testing?
• What criteria should be used to establish which genetic variants of a locus should be included for diagnostic purposes? • Is it necessary to have evidence to demonstrate cost effectiveness before recommending clinical use of pharmacogenetic tests?
In this section, the personnel performing pharmacogenetics testing rank first in the recommendation, followed by robust and optimized diagnostic methods for DNA analysis from fresh whole blood, dried whole blood spots, isolated nucleated blood cells, and oral epithelial cells obtained from either buccal scraping or saliva. Laboratories should report a description of all physical characteristics of the genetic locus that are being determined by the assay. Laboratories should provide turn-around times that are consistent with the clinical application of pharmacogenetic test results. In general, the goal is for the physician to be advised of the patient's genotype in due time to avoid any risk for the patient.
Before the pharmacogenetics testing be considered for purposes of cost-effectiveness as applied to general screening, a series of important questions should be addressed. Some examples are:
• What is the frequency of the genetic polymorphism?
• How closely is the polymorphism linked to a consistent phenotypic drug response?
• Are there metabolic, environmental or other significant influences on drug response?
• What are the sensitivity and specificity of the genomic test?
• When reporting genotype information from pharmacogenetic tests, the clinical laboratories must keep in mind that the end user of this information will most likely be the physician or other healthcare provider. It is usually the physician who will report the findings to the patient and take action using the test result. For the physician to correctly interpret the genotype information, it is beneficial that he or she have the complete diagnostic setting of the patient including present and past drug regimens, medical history and lifestyle. Questions for consideration are:
• What information should accompany the reported result?
• Should the result be linked to a specific drug usage (as indicator)? Should drug "dosing and usage" information accompany the test result? • Should laboratories reporting pharmacogenetic test results have a genetic counseling component or service available or by referral? • Should manufacturers of IVD used for providing pharmacogenetic tests be required to supply evidence of specific use for every drug, or by class? • Are there unique or specific limitations to be considered regarding confidential reporting of pharmacogenetic test results?
In recommendation, the authors state that laboratories reporting pharmacogenetic genotype test results should be prepared to provide an educational resource to recipients of the test results to explain the complexity of the metabolic pathways involved and also be prepared to provide guidance as to which genes should be tested for a given clinical situation when that is known. Many other recommendations are counted in consideration of the section. This section describes one of the most challenging aspects of transitioning the science of pharmacogenetics to the bedside while establishing criteria for its clinical application. The approach for these present practice guidelines is to take several key examples and use them as a basis on which to set criteria for documenting future development of these services to medical practice. Three models are presented in which pharmacogenetic test results have proved useful to establish criteria for clinical applications: warfarin (anticoagulation), atomoxetine (psychiatry), and irinotecan (oncology). These three models combined demonstrate several strategies and concepts for future development of pharmacogenetics applications. Questions for consideration were:
• Which are the most current variant alleles for CYP2D6, 2C9, and 2C19 recommended for clinical use? • What set of criteria (characteristics) should be required of a pharmacogenetic test to make it clinically useful?
• What examples are available that can presently be used as models for application of pharmacogenetic testing in clinical settings? warfarin (2C9 and VKOR), atomoxetine (2D6), irinotecan (UGT1A1)? • What models of pharmacogenetics-genotyping are available which can serve to establish dosing adjustment rules based on pharmacogenetic information? • What role should the clinical laboratory play in developing the use of pharmacogenetic testing?
In recommendation, the most current variant alleles are recommended when performing pharmacogenetics-genotyping for CYP2D6, 2C9, and 2C19, as well as its clinical use. As examples, warfarin, atomoxetine and irinotecan are presented. This section addresses medications which require monitoring of their concentrations in blood, i.e. those where narrow therapeutic concentration ranges in blood are required for efficacy, and where toxicity is a persistent problem. As the discipline of pharmacogenetics finds its way into clinical practice, the combination of traditional TDM and pharmacogenetics must be explored to achieve optimum utilization of the combined information they provide. In essence, pharmacogenetics provides information that allows the clinician to make a determination of appropriateness and risk of drug therapy prior to the initiation of therapy. Pharmacogenetics may then have an additional place in selecting drug or dosage alterations during the treatment for a disease process. Questions for consideration are:
• Will use of pharmacogenetics information preclude or require TDM in future? and, How should standard TDM practices be modified to account for pharmacogenetic variation? • Are there specific clinical situations demonstrative of both TDM and pharmacogenetics information having complementary value? • How can TDM be best utilized in establishing the predictive value of pharmacogenetic tests, as end point, etc.?
It is recommended that pharmacogenetics testing information be used for the initial selection of drugs or doses for some agents, with a note that the clinician should be aware of the possibility of a significant variability using pharmacogenetics information to design a drug regimen, and that TDM is still essential to monitor therapeutic response and toxicity. This section is focused on other applications of pharmacogenetics including its use in: production of targeted drugs by pharmaceutical companies; forensics; safer distribution of medications by pharmacist; environmental toxicology (toxicogenomics); predicting addiction to substances; etc. The information is still rather green, however, evolving rapidly in many of these areas. Yet, in the areas of forensics and drug dispensing some recommendations are worthy of consideration. Considering regulatory considerations in this section, the evaluation and approval of pharmacogenomic tests can be categorized into two broad aspects: analytical validation and clinical usefulness of the test. Questions for consideration are:
• When will a test be "required", when is a test "recommended"?
• When should the label state that the test is "available"?
According to the recommendation, a test may be required for therapy when the drug or the biological is co-developed with a test. Patients are eligible to receive a treatment only if a test result is obtained prior to treatment initiation. The test may be recommended prior to the selection of a therapy and/or the selection of a dose for a particular population deficient in activity of a polymorphic enzyme involved in the inactivation of the drug/biological.
10. Farkas D. Glossary -definition useful in understanding pharmacogenetics. The Glossary is printed as a whole text at the end of this Handbook.
In Conclusion
A hundred years ago, clinicians prescribed a drug only on the basis of physical examination. At the end of the 20 th century, therapeutic decision was greatly facilitated by laboratory support and the process of therapeutic drug monitoring. Now we have entered a new era with pharmacogenetics and pharmacogenomics, which appear highly promising in enhancing the support to therapeutic decision making, predicting patients who are most likely to respond best to a particular drug, or in whom the drug will yield optimal effects.
The development and release of these LMPG in Pharmacogenetics in terms of methodology, genotyping profiles, interpretation of pharmacogenetic results, quality control and standardization, thereby upgrading the overall healthcare level and service cost effectiveness while reducing the morbidity and mortality rates due to ADR, will ensure appropriate and systematic assessment of pharmacogenetic testing and its optimal application in therapy individualization.
